Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. DOI:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• Quint JK, O’Leary C, Venerus A, et al. Prescribing pathways to triple therapy: a Multi-Country, retrospective observational study of adult patients with chronic obstructive pulmonary disease. Pulm Ther. 2020;6(2):333–350.
   PubMedGoogle Scholar
• Rodriguez-Roisin R, Rabe KF, Vestbo J, et al. Global initiative for chronic obstructive lung disease (GOLD) 20th anniversary: a brief history of time. Eur Respir J. 2017;50(1):1700671.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced All-Cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, Double-Blind, multicenter, Parallel-Group study. Am J Respir Crit Care Med. 2021;203(5):553–564.
   PubMed Web of Science ®Google Scholar
• Vestbo J. Fixed triple therapy in chronic obstructive pulmonary disease and survival. Living better, longer, or both?Am J Respir Crit Care Med. 2020;201(12):1463–1464.
   PubMed Web of Science ®Google Scholar
• Calverley P. Reigniting the TORCH: chronic obstructive pulmonary disease mortality and inhaled corticosteroids revisited. Am J Respir Crit Care Med. 2021;203(5):531–532.
   PubMed Web of Science ®Google Scholar
• Suissa S. Perplexing mortality data from triple therapy trials in COPD. Lancet Respir Med. 2021 Jul;9(7):684–685.
   PubMed Web of Science ®Google Scholar
• Suissa S, Drazen JM. Making sense of triple inhaled therapy for COPD. N Engl J Med. 2018;378(18):1723–1724.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ariel A. Triple therapy trials in COPD: a precision medicine opportunity. Eur Respir J. 2018;52(6):1801848.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Kostikas K. Single-Inhaler triple versus dual therapy in patients with COPD. New Engl J Med. 2018;379(6):590–593.
   PubMed Web of Science ®Google Scholar
• Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us?N Engl J Med. 2016;375(23):2293–2297.
   PubMed Web of Science ®Google Scholar
• Frieden TR. Evidence for health decision making - beyond randomized, controlled trials. N Engl J Med. 2017;377(5):465–475.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of initial LAMA versus LABA in COPD: Real-World cohort study. COPD. 2021;18(1):1–8.
   PubMedGoogle Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: clinical practice research datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740–1740g.
   PubMed Web of Science ®Google Scholar
• Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14.
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836.
   PubMed Web of Science ®Google Scholar
• Quint JK, Mullerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the clinical practice research datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540.
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771–782.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. DOI:10.1016/S2213-2600(18)30368-0
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort study in Real-World clinical practice. CHEST. 2020;157(4):846–855.
   PubMed Web of Science ®Google Scholar
• Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1–6.
   PubMed Web of Science ®Google Scholar
• Suissa S, Moodie EE, Dell’Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459–468.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657.
   PubMedGoogle Scholar
• Meropol SB, Metlay JP. Accuracy of pneumonia hospital admissions in a primary care electronic medical record database. Pharmacoepidemiol Drug Saf. 2012;21(6):659–665.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice . CHEST. 2019;155(6):1158–1165.
   PubMed Web of Science ®Google Scholar
• Myers JA, Rassen JA, Gagne JJ, et al. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011;174(11):1213–1222.
   PubMed Web of Science ®Google Scholar
• Rebordosa C, Plana E, Aguado J, et al. GOLD assessment of COPD severity in the clinical practice research datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019;28(2):126–133.
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations . Eur Respir J. 2012;40(6):1324–1343.
   PubMed Web of Science ®Google Scholar
• Suissa S. Run-in bias in randomised trials: the case of COPD medications. Eur Respir J. 2017;49(6):1700361.
   PubMed Web of Science ®Google Scholar
• FDA. Food and Drug Aministration; 2020. Available from: https://www.fda.gov/media/143921/download.
   Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. DOI:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–1826.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Leather D, Diar BN, et al. Effectiveness of fluticasone Furoate-Vilanterol for COPD in clinical practice. N Engl J Med. 2016;375(13):1253–1260.
   PubMed Web of Science ®Google Scholar
• Bass DA, Gonwa TA, Szejda P, et al. Eosinopenia of acute infection: production of eosinopenia by chemotactic factors of acute inflammation. J Clin Invest. 1980;65(6):1265–1271.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker?Lancet Respir Med. 2017;5(9):747–759. DOI:10.1016/S2213-2600(17)30217-5
   PubMed Web of Science ®Google Scholar